Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192567 | 0.95 | MEN1 (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL481736 | 0.95 | MEN1 (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL640559 | 0.95 | MEN1 (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL31587983 | 0.94 | MEN1 (0.53) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL28110777 | 0.90 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6197 | 0.89 | NR1H2 (0.49) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL321665 | 0.89 | NR1H2 (0.49) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL346504 | 0.89 | NR1H2 (0.49) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31420849 | 0.89 | BACE1 (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31420851 | 0.89 | BACE1 (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7432379-B2 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | HPGD 260/4885MEN1 1010/4885ALDH1A1 3054/4885 |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | HPGD 797/4885MEN1 3044/4885ALDH1A1 2017/4885 |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | HPGD 2412/4885MEN1 3887/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.